An interventional study of Low-Dose High-Intensity Laser Therapy (10 J/cm²) and Medium-Dose High-Intensity Laser Therapy (15 J/cm²) in Knee Osteoarthritis, sponsored by Al Hayah University In Cairo. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Al Hayah University In Cairo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Osteoarthritis, Knee with a site in Egypt — 28 open to participants now, 34 under way, 1 of them phase 3. Osteoarthritis, Knee · Egypt.
Among the 91 studies in Osteoarthritis, Knee with a site in Egypt, this one is the 5th largest by planned enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2025, is one of 76 with no phase, reaches primary completion later than 25 of the 33 other live ones, and was the 62nd registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →28 of the 91 studies in Osteoarthritis, Knee with a site in Egypt are open now. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
National Cancer Institute, Egypt · Sites in Egypt
Ages 40+
Tanta University · Sites in Egypt
Ages 50+
Tanta University · Sites in Egypt
Ages 50+
Tanta University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2011; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 62 across the 83 interventional studies, 69 across the 8 observational. Of the 50 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 91 has an industry lead sponsor. The 10 most frequent:
Al Hayah University In Cairo is the lead sponsor of 16 studies on the registry; 12 are open to participants now.
Al Hayah University In Cairo has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
11 of the studies in Osteoarthritis, Knee with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07047040Phase 3Assiut UniversityAnalgesic Efficacy of Pre-operative Dose of Ketorolac and Gabapentin | 2027-10-30 |
| NCT07664371Tanta UniversityCryoneurolysis Versus Radiofrequency in Knee Osteoarthritis | 2026-11 |
| NCT07468734German International UniversityShock Wave Versus Traditional Physical Therapy for Adult Chronic Knee Osteoarthritis | 2026-11-30 |
| NCT07666347Tanta UniversityIntraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis | 2026-12-01 |
| NCT07478861Beni-Suef UniversityWhole-body Vibration Training on the Elderly With Combined Bilateral Knee Osteoarthritis | 2027-02-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in Osteoarthritis, Knee with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to find the best settings (dose) for High-Intensity Laser Therapy (HILT) to reduce pain and improve function in people with moderate knee osteoarthritis. Participants will be randomly assigned to receive one of three different doses of HILT (low, medium, or high) or a sham (placebo) laser treatment, three times a week for four weeks. The main outcomes measured will be changes in knee pain (using a pain scale) and knee function (using a questionnaire) from the beginning to the end of the 4-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between 45 and 75 years, inclusive. Clinical diagnosis of knee osteoarthritis according to American College of Rheumatology (ACR) criteria (knee pain plus at least 3 of 6: age >50, morning stiffness \<30 min, crepitus, bony tenderness, bony enlargement, no palpable warmth).
Radiographic evidence of knee osteoarthritis corresponding to Kellgren-Lawrence grade II or III in the target knee.
Average knee pain intensity ≥ 4 on a 10-cm Visual Analogue Scale (VAS) during weight-bearing activities in the past week.
Willingness and ability to attend 3 sessions per week for 4 weeks and attend all assessment sessions.
Exclusion Criteria:
Previous surgery on the index knee (including arthroscopy within the last year or joint replacement).
Diagnosis of inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, gout).
Intra-articular or hyaluronic acid injection in the index knee within the last 3 months.
comorbidities that could interfere with participation or assessment (e.g., severe uncontrolled cardiovascular disease, severe pulmonary disease, significant neurological deficits affecting the lower limb).
Presence of skin conditions (e.g., infection, open wounds, eczema, photosensitivity disorders) in the area designated for laser treatment.
Current use of anticoagulant medication (e.g., warfarin, DOACs) due to potential risk, unless stable and cleared by physician. (Consider if this is truly necessary based on HILT mechanism).
History of cancer in the treatment area or active elsewhere. Known photosensitivity or use of photosensitizing medications. Pregnancy, planning pregnancy, or breastfeeding. Participation in another interventional clinical trial within the last 30 days. Inability to understand or communicate in the study language.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive High-Intensity Laser Therapy at a dosage of 10 J/cm² per treatment zone, 3 times per week for 4 weeks (12 sessions total).
Device: Low-Dose High-Intensity Laser Therapy (10 J/cm²)
Participants receive High-Intensity Laser Therapy at a dosage of 15 J/cm² per treatment zone, 3 times per week for 4 weeks (12 sessions total).
Device: Medium-Dose High-Intensity Laser Therapy (15 J/cm²)
Participants receive High-Intensity Laser Therapy at a dosage of 20 J/cm² per treatment zone, 3 times per week for 4 weeks (12 sessions total).
Device: High-Dose High-Intensity Laser Therapy (20 J/cm²)
Participants receive a sham High-Intensity Laser Therapy procedure using the same device and application technique, but with no energy delivered, 3 times per week for 4 weeks (12 sessions total).
Device: Sham High-Intensity Laser Therapy
Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 10 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 15 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 20 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
Sham procedure mimicking active HILT using the same Nd:YAG laser device (BTL-6000). Same setup, patient positioning, scanning technique over identical zones, and session duration/frequency (3x/week, 4 weeks, 15-20 min). Device powered on with visual/auditory cues active, but no laser energy emitted. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
Change in Knee Pain Intensity
Visual Analogue Scale (VAS) for Pain: Change from baseline in average knee pain over the past week, measured on a 10 cm horizontal VAS, where 0 cm = no pain and 10 cm = worst imaginable pain. Higher scores indicate worse pain. Minimal Clinically Important Difference (MCID) estimated at 1.25 cm.
Time frame: Baseline (T0), Mid-treatment (T1 - after 6 sessions), Post-treatment (T2 - after 12 sessions), 3-month Follow-up (T3)
Change in Knee Osteoarthritis Symptoms and Function
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Change from baseline in the total WOMAC score (Likert scale version 3.1). The WOMAC assesses pain (5 items), stiffness (2 items), and physical function (17 items). Total score ranges from 0-96, with higher scores indicating worse symptoms/function.
Time frame: Baseline (T0), Mid-treatment (T1), Post-treatment (T2), 3-month Follow-up (T3)
Change in Knee Range of Motion (Flexion and Extension)
Change from baseline in active knee flexion and extension range of motion, measured in degrees using a standard goniometer.
Time frame: Baseline (T0), Post-treatment (T2), 3-month Follow-up (T3)
Change in Functional Mobility
Timed Up and Go Test (TUG). Change from baseline in the time (in seconds) taken to rise from a standard chair, walk 3 meters, turn, walk back, and sit down. Shorter times indicate better mobility.
Time frame: Baseline (T0), Post-treatment (T2), 3-month Follow-up (T3)
Incidence of Adverse Events
Number, type, and severity of any adverse events (AEs) reported by participants or observed by study staff throughout the study duration, particularly those potentially related to HILT (e.g., skin irritation, burns, increased pain).
Time frame: Throughout study participation (up to 3-month follow-up)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Mar 2027, 22 months later.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 22 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al Hayah University In Cairo